The ORRs of PARPi/anti-PD-1 in both SCLC and gynecologic tumors were a little higher than other studies [12, 14], maybe owing to earlier treatment line, combined chemotherapy and different population characteristics. This evidence concerns the gene PDCD1 and female reproductive system neoplasm.